Clinical Trial Results:
A randomized, double-blind, multi-center study to assess safety and tolerability of different oral doses of
BAY 94-8862 in subjects with stable chronic heart failure with left ventricular systolic dysfunction and
mild (Part A) or moderate (Part B) chronic kidney disease versus placebo (Part A) or versus placebo and
spironolactone (Part B)
Summary
|
|
EudraCT number |
2011-000301-45 |
Trial protocol |
SE FI DE DK BE AT CZ |
Global completion date |
16 Jul 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 May 2016
|
First version publication date |
01 May 2016
|
Other versions |
|
Summary report(s) |
Bayer Study Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.